GreyBird Ventures menu

PHILOSOPHY

Precision Medicine and Precision Diagnostics

All healthcare starts with diagnosis. Diagnostics for precision medicine must:

Provide specific characterization of an individual patient’s unique disease and biology.
Accurately identify individual patients who will and who will not respond to therapies that are increasingly targeted and increasingly expensive.
Create an environment for an efficient healthcare system.

GreyBird has the goal to invest in companies that can help to eliminate “trial and error” medicine with high-specificity diagnostics and generate value for patients, providers, developers of therapies, and those who pay for healthcare.

For every patient that they help, the ten highest grossing drugs in the United States fail to help up to 24 people.

Why Invest in Precision Diagnostics

GreyBird Investment Opportunities

In spite of growing R&D expenditures, truly new technologies are not coming from the largest multi-national diagnostic technology companies. They are coming from entrepreneurs, who are creating an appetite for M&A. The demand for our portfolio is already here.

Industry Dynamics

Poor development productivity
Lack of organic growth
Risk reduction
M&A initiatives

Scientific Discovery

‘Omics revolution
New detection technologies
Targeted therapies
Personal monitoring devices
Advanced analytics

Healthcare Economics

Access vs. cost control
Global structural growth
Global clinical trials
Unnecessary, ineffective, and inefficient care avoidance

We will improve health and create wealth, by investing in technologies to change healthcare from probabilistic and population-based, to precise, predictive and personal.

Our Approach and Why it Matters

GREYBIRD WAS FOUNDED AND DELIVERS ON FIVE PILLARS OF VALUE-CREATING DIFFERENTIATION

1. Dedicated Focus

Next generation Precision Diagnostics, where we have deep domain competence and market tailwinds

2. Investor Friendly

We openly share investment analyses and preserve an opt-out option for our investors

3. Global Influence

We have proprietary connections to global companies, markets, and trend-setting projects

4. Engaged Diligence

We are not passive investors, starting with an operational engagement even before we invest

5. Transformational Companies

We can afford to be patient and will invest only in companies we believe can have a disruptive impact and the potential for large exit multiples

Our unique “Engaged Diligence” process dramatically increases transparency

We skip the typical due-diligence show and instead, during our months-long Engaged Diligence we learn about the company and its people, products, and processes:

Join boards
Craft clinical trials
Solve technical problems
Draft strategy plans
Identify operational issues
Find strategic partners

TESTIMONIALS

“GreyBird was extremely helpful to us well prior to their investment. They helped shape our strategy, opined on marketing documents, helped shape our presentations, and even contributed family members as beta testers. They remain deeply involved and committed to our success.”

Zeb Kimmel, CEO, Atlas5D

“GreyBird claims that they are not passive investors – and they are not. They encourage, demand and help us improve as individuals and as a company. As Board Members, they provide guidance and exert control as appropriate, but always leave enough room for the CEO to lead and continue to develop. We feel fortunate that they chose to invest in our company.”

Jochen Kohlhaas, CEO, Hummingbird Diagnostics

“Prior to investing, GreyBird helped us to craft our business plan and focus on the commercialization of the Lyme test as our first product. They have introduced us at very high levels to potential strategic partners and never fail to give us some free advertising whenever possible.”

Ross Dunlap, CEO, Ceres Nanosciences

“GreyBird helped us see the necessity of narrowing the scope of our product investments to a solution that accelerated our initial market penetration. They also provided much-needed introductions to strategic partners. While we cannot (yet) count ourselves among their portfolio companies, we have greatly benefitted from their ‘engaged diligence’ process.”

Nick Berens, CEO, TransMed

Our “Ethical Filter” is both a moral and a financial asset

Solves a serious or unsolved problem?
Cost-effective?
Possible new Standard of Care?
Potential for inappropriate use?
Potential negative consequences?
Potential for harm?
Would I recommend it for my family?
Would I pay for it myself?

Regulatory approval proves medical benefit? We disagree. Reimbursed technologies that have been exploited or result in unnecessary care are too numerous to list. We take this one step further and analyze eight questions to help determine medical appropriateness and long-term clinical consequences. The advantage is not only humanitarian. It reduces risk of poor global acceptance or a future disruptive reimbursement decrease.

GreyBird Ventures

is named after the arctic tern, a bird that migrates 71,000 km annually. As they can live for 30 years, this is the lifetime equivalent of three trips to the moon and back. Not bad for a 100 gram bird. We strive to emulate its size to performance ratio as well as its global reach.

MEET THE PEOPLE

For additional information, please contact: greybird@greybirdventures.com

GreyBird Ventures LLC (“GreyBird”) has prepared the contents of this web site (“Site”) solely for informational purposes and to assist prospective investors who view this Site (the “Recipients”) in deciding whether to proceed with a further investigation of investments managed by GreyBird. Under no circumstances shall this Site be deemed or construed to be an offer to sell, or the solicitation of an offer to buy, any securities, and it is not intended to be the basis of any investment decision or any decision to subscribe to a GreyBird investment vehicle (“Investments”). GreyBird does not make any representation or warranty, expressed or implied, as to the accuracy or completeness of information on the Site.

This Site contains certain statements and estimates made by GreyBird with respect to the anticipated future performance of its Investments and portfolio companies. Such statements and estimates reflect various assumptions concerning anticipated results, which assumptions may or may not prove to be correct. No representations or warranties are made as to the accuracy of such statements or estimates. This Site is for information only and intended for persons reasonably believed to have sufficient expertise to understand the risks involved.

Past performance is not necessarily indicative of future results, and there can be no assurance that the Investments will achieve comparable results or that GreyBird will be able to implement its strategy or achieve its investment objectives. This Site does not constitute an offer to sell or the solicitation of an offer to buy in any state or other U.S. or non-U.S. jurisdiction to any person to whom it is unlawful to make such offer or solicitation in such state or jurisdiction. This offering does not constitute an offer of interests in the investment programs managed by GreyBird (the “Interests”) to the public, and no action has been or will be taken to permit a public offering in any jurisdiction where action would be required for that purpose. The Interests may not be offered or sold, directly or indirectly, and contents of this site may not be copied, reproduced, and/or distributed in any jurisdiction, except in accordance with the legal requirements applicable in such jurisdiction. Prospective investors should inform themselves as to the legal requirements and tax consequences within the countries of their citizenship, residence, domicile and place of business with respect to the acquisition, holding or disposal of Interests, and any non-U.S. exchange restrictions that may be relevant thereto.

Moreover, certain information contained in this Site constitutes “forward-looking” statements, which can be identified by the use of forward-looking terminology such as “may”, “will”, “seek”, “should”, “expect”, “anticipate”, “project”, “estimate”, “intend”, “continue”, “target”, or “believe” or the negatives thereof or other variations thereon or comparable terminology. Due to various risks and uncertainties, including those set forth herein, actual events or results, projected market conditions, interest rate movements, or consumer or investing trends, the actual performance of the Investments may differ materially from that which is reflected or contemplated in such forward-looking statements.

THE INTERESTS HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), THE SECURITIES LAWS OF ANY STATE OR ANY OTHER APPLICABLE SECURITIES LAWS IN RELIANCE UPON EXEMPTIONS FROM THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND SUCH LAWS. SUCH INTERESTS MUST BE ACQUIRED FOR INVESTMENT ONLY AND MAY NOT BE OFFERED FOR SALE, PLEDGED, HYPOTHECATED, SOLD, ASSIGNED OR TRANSFERRED AT ANY TIME EXCEPT IN COMPLIANCE WITH (I) THE SECURITIES ACT, ANY APPLICABLE STATE SECURITIES LAWS, AND ANY OTHER APPLICABLE SECURITIES LAWS; AND (II) THE TERMS AND CONDITIONS OF THE RELEVANT OPERATING AGREEMENT GOVERNING THE INVESTMENT. THE INTERESTS MAY NOT BE TRANSFERRED OF RECORD EXCEPT IN COMPLIANCE WITH SUCH LAWS AND SUCH OPERATING AGREEMENT. THEREFORE, PURCHASERS OF SUCH INTERESTS WILL BE REQUIRED TO BEAR THE RISK OF THEIR INVESTMENT FOR AN INDEFINITE PERIOD OF TIME.